Temferon Emerging Drug Insight

"Temferon Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Temferon for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the Temferon for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Temferon for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Temferon market forecast analysis for GBM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

Temferon is a lentivirus-based hematopoietic stem progenitor cell immunotherapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor-infiltrating monocytes (Tie2 expressing monocytes – TEMs), Temferon generates immune responses to any TEMs-positive tumors.

Underlying Temferon is a platform technology that controls the expression of the therapeutic payload within the tumor microenvironment and can be applied to multiple payloads. As a cell therapy, the impact is enduring, creating potentially life-long tumor surveillance.

Genenta expects to complete the enrollment of its Phase I/IIa trial by the first half of 2023 and initiate Phase II by the second half of 2023. The company also expects to present data from Phase I/IIa after an 18-month follow-up from Cohort 6 and Cohort 7 by the second half of 2024.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Temferon description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on Temferon regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Temferon research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Temferon.
• The report contains forecasted sales of Temferon for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for Temferon in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Temferon Analytical Perspective by DelveInsight

• In-depth Temferon Market Assessment

This report provides a detailed market assessment of Temferon for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Temferon Clinical Assessment

The report provides the clinical trials information of Temferon for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Temferon dominance.
• Other emerging products for GBM are expected to give tough market competition to Temferon and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Temferon in GBM.
• Our in-depth analysis of the forecasted sales data of Temferon from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Temferon in GBM

Key Questions

• What is the product type, route of administration and mechanism of action of Temferon?
• What is the clinical trial status of the study related to Temferon in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Temferon development?
• What are the key designations that have been granted to Temferon for GBM?
• What is the forecasted market scenario of Temferon for GBM?
• What are the forecasted sales of Temferon in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to Temferon for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?